A pilot transcriptomic study of a novel multitargeted BRT regimen for anti–MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy

A pilot transcriptomic study of a novel multitargeted BRT regimen for anti–MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy

BackgroundAnti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is associated with severe outcomes, primarily due to rapidly progressive interstitial lung disease (RP-ILD), which is often refractory to standard therapies such as calcineurin inhibitors (e.g., tac...

Full description

Saved in:
Bibliographic Details
Main Authors: Moe Tokunaga, Yu Nakai, Yoshiharu Sato, Mitori Hiratsuka, Yoshinori Matsumoto, Takeshi Nakatsue, Takako Saeki, Takatsune Umayahara, Jun Wada, Yoshinobu Koyama
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Immunology
Subjects:
anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)
JAK inhibitor
baricitinib
rituximab
multitargeted treatment
IFN signature
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1568338/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1568338/full

Similar Items